Bausch + Lomb (NYSE:BLCO) CAO Frederick Munsch Sells 52,900 Shares

Bausch + Lomb Corporation (NYSE:BLCO) CAO Frederick Munsch sold 52,900 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $16.78, for a total value of $887,662.00. Following the completion of the sale, the chief accounting officer owned 45,831 shares in the company, valued at approximately $769,044.18. This represents a 53.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Bausch + Lomb Stock Down 0.4%

Shares of Bausch + Lomb stock opened at $16.81 on Thursday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.55 and a quick ratio of 1.02. Bausch + Lomb Corporation has a 1-year low of $13.77 and a 1-year high of $18.92. The business’s fifty day moving average price is $16.13 and its two-hundred day moving average price is $16.39. The company has a market capitalization of $6.00 billion, a P/E ratio of -35.02, a PEG ratio of 0.55 and a beta of 0.56.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. HC Wainwright boosted their price target on shares of Bausch + Lomb from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. UBS Group started coverage on shares of Bausch + Lomb in a report on Thursday, July 30th. They issued a “buy” rating and a $21.00 price objective for the company. Deutsche Bank Aktiengesellschaft set a $16.00 price objective on shares of Bausch + Lomb in a research note on Thursday, April 30th. Weiss Ratings cut Bausch + Lomb from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 7th. Finally, Evercore set a $17.00 target price on Bausch + Lomb in a research report on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $18.75.

Institutional Trading of Bausch + Lomb

Hedge funds have recently bought and sold shares of the company. Cetera Investment Advisers grew its stake in shares of Bausch + Lomb by 3.9% in the 4th quarter. Cetera Investment Advisers now owns 18,713 shares of the company’s stock valued at $320,000 after buying an additional 711 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Bausch + Lomb by 38.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,757 shares of the company’s stock worth $64,000 after buying an additional 1,039 shares during the last quarter. Handelsbanken Fonder AB raised its stake in shares of Bausch + Lomb by 5.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 22,000 shares of the company’s stock valued at $364,000 after acquiring an additional 1,100 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Bausch + Lomb by 104.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock worth $38,000 after purchasing an additional 1,136 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in Bausch + Lomb by 31.2% in the 4th quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock worth $101,000 after purchasing an additional 1,403 shares during the last quarter. 11.07% of the stock is owned by hedge funds and other institutional investors.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.